Novel drug delivery systems: Potential in improving topical delivery of antiacne agents

Skin Pharmacology and Physiology

Volumn 19, Issue 1, 2005, Pages 2-16

  Date, A A ^a   Naik, B ^a   Nagarsenker, M S ^a  

^a BOMBAY COLLEGE OF PHARMACY   (India)

Author keywords

Acne; Liposomes; Microemulsions; Nanoparticles, solid lipid; Topical treatment

Indexed keywords

ADAPALENE; AMINOLEVULINIC ACID; ANTI ACNE AGENT; ANTIANDROGEN; AZELAIC ACID; AZITHROMYCIN; BENZOYL PEROXIDE; CARBOMER; CHLOROXYLENOL; CLINDAMYCIN; CYPROTERONE ACETATE; DYNASAN; ECONAZOLE; ERYTHROMYCIN; GLYCEROL BEHENATE; GLYCOLIC ACID; ISOTRETINOIN; KLIMICIN; LACTIC ACID; LIPID; LIPOEARLS; LIPOSOME; MANDELIC ACID; NADIFLOXACIN; NANOPARTICLE; NICOTINAMIDE; NIOSOME; POLIDOCANOL; PYRUVIC ACID; RETINOIC ACID; ROZA; SALICYLIC ACID; SLN; SOFTISAN; SULFACETAMIDE; SULFUR; T 3912; TAZAROTENE; TEA TREE OIL; TYLOXAPOL; UNCLASSIFIED DRUG; UNINDEXED DRUG; WITEPSOL;

ACNE; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRY SKIN; ERYTHEMA; HUMAN; HYDROGEL; MICROEMULSION; PRIORITY JOURNAL; PRURITUS; REVIEW; SKIN ABRASION; SKIN BURNING SENSATION; SOLID;

ACNE VULGARIS; ADMINISTRATION, CUTANEOUS; ANIMALS; DERMATOLOGIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS;

EID: 28744444162     PISSN: 16605527     EISSN: None     Source Type: Journal    
DOI: 10.1159/000089138     Document Type: Review

References (95)

1. Brajac I, Lidija Bilic-Zulle L, Tkalcic M, Loncarek K, Gruber F: Acne vulgaris: myths and misconceptions among patients and family physicians. Patient Educ Couns 2004;54:21-25.
2. Befed WF: The evaluation and management of acne: economic considerations. J Am Acad Dermatol 1995;32:552-556.
3. Thiboutot D: New treatments and therapeutic strategies for acne. Arch Fam Med 2000;9:179-187.
4. Gupta MA, Gupta AK: Depression and suicidal ideation in dermatology patients with acne, alopecia aerata, atopic dermatitis and psoriasis. Br J Dermatol 1998;78:451-456.
5. Cunliffe WJ, Holland DB, Clark SM, Stables GI: Comedogenesis: some new aetiological, clinical and therapeutic strategies. Dermatology 2003;206:11-16.
6. Zouboulis CC, Piquero-Martin J: Update and future of systemic acne treatment. Dermatology 2003;206:37-53.
7. Zouboulis CC, Eady A, Philpott M, Goldsmith LA, Orfanos C, Cunliffe WC, Rosenfield R: What is the pathogenesis of acne? Exp Dermatol 2005;14:143-152.
8. Bataille V, Snieder H, MacGregor AJ, Sasieni P, Spector TD: The influence of genetics and environmental factors in the pathogenesis of acne: a twin study of acne in women. J Invest Dermatol 2002;119:1317-1322.
9. Herane MI, Ando I: Acne in infancy and acne genetics. Dermatology 2003;206:24-28.
10. Toyoda M, Morohashi M: New aspects in acne inflammation. Dermatology 2003;206:17-23.
11. Kim J, Ochoa MT, Krutzik SR, Takeuchi O, Uematsu S, Legaspi AJ, Brightbill HD, Holland D, Cunliffe WJ, Akira S, Sieling PA, Godowski PJ, Modlin RL: Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J Immunol 2002;169:1535-1541.
12. Schäfer T, Nienhaus A, Vieluf D, Berger J, Ring J: Epidemiology of acne in the general population: the risk of smoking. Br J Dermatol 2001;145:100-104.
13. Gollnick H, Cunliffe W, Berson D, Dreno B, Finlay A, Leyden J, Shalita A, Thiboutot D: Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 2003;49:S1-S37.
14. Krautheim A, Gollnick H: Transdermal penetration of topical drugs used in the treatment of acne. Clin Pharmacokinet 2003;42:1287-1304.
15. Gold MH: A multi-center study of photodynamic therapy in the treatment of moderate to severe inflammatory acne vulgaris with topical 20% 5-aminolevulinic acid and a new intense pulsed light source. J Am Acad Dermatol 2004;50(suppl 1):P14.
16. Katsambas AD, Nicolaidou E: Acne, perioral dermatitis, flushing, and rosacea: unapproved treatments or indications. Clin Dermatol 2000;18:171-176.
17. Ikeno H, Ohmori K, Monma T: An open study comparing efficacy of sodium 5% L-ascorbyl-2-phosphate lotion versus 5% benzoylperoxide cream in the treatment of acne vulgaris. J Am Acad Dermatol 2004;50(suppl 1):P18.
18. Rougier AM, Pierard G: Nudging acne by topical beta-lipohydroxy acid (LHA), a new comedolytic agent. J Am Acad Dermatol 2004;50(suppl 1):P19.
19. Zouboulis CC: Retinoids - which dermatological indications will benefit in the near future? Skin Pharmacol Appl Skin Physiol 2001;14:303-315.
20. Yamakawa T, Mitsuyama J, Hayashi K: In-vitro and in-vivo anti-bacterial activity of T-3912, a novel non-fluorinated topical quinolone. J Antimicrob Chemother 2002;49:455-465.
21. Boutli F, Zioga M, Koussidou T, Ionnaides D, Mourellou O: Comparison of chloroxylenol 0.5% plus salicylic acid 2% cream and benzoyl peroxide 5% gel in the treatment of acne vulgaris: a randomized double-blind study. Drugs Exp Clin Res 2003;29:101-105.
22. Carson CF, Riley TV: Susceptibility of Propionibacterium acnes to the essential oil of Melaleuca alternifolia. Lett Appl Microbiol 1994;19:24-25.
23. Gulati M, Grover M, Singh S, Singh M: Lipophilic drug derivatives in liposomes. Int J Pharm 1998;165:129-168.
24. Mezei M, Gulasekharam V: Liposomes - a selective drug delivery system for the topical route of administration. Lotion dosage form. Life Sci 1980;26:1473-1477.
25. Mezei M, Gulasekharam V: Liposomes - a selective drug delivery system for the topical route of administration: gel dosage form. J Pharm Pharmacol 1982;34:473-474.
26. Schreier H, Bouwstra J: Liposomes and niosomes as topical drug carriers: dermal and transdermal drug delivery. J Control Release 1994;30:1-15.
27. Lieb LM, Ramachandran C, Egbaria K, Weiner N: Topical delivery enhancement with multilamellar liposomes into pilosebaceous units. I. In-vitro evaluation using fluorescent techniques with the hamster ear model. J Invest Dermatol 1992;99:108-113.
28. Lauer AC, Lieb LM, Ramachandran C, Flynn GL, Weiner ND: Transfollicular drug delivery. Pharm Res 1995;12:179-186.
29. Skalko N, Cajkovac M, Jalenjack I: Liposomes with clindamycin hydrochloride in the therapy of acne vulgaris. Int J Pharm 1992;85:97-101.
30. Honzak L, Sentjurc M: Development of liposome encapsulated clindamycin for treatment of acne vulgaris. Pflügers Arch 2000;440(suppl 5):R44-R45.
31. Foong WC, Harsany BB, Mezei M: Biodisposition and histological evaluation of topically applied retinoic acid in liposomal, cream and gel dosage forms; in Hanin I, Pepeu G (eds): Phospholipids. New York, Plenum Press, 1990, pp 279-282.
32. Masini V, Bonte F, Meybeck A, Wepierre J: In vitro percutaneous absorption and in vivo distribution of retinoic acid in liposomes and in a gel on hairless rats. Proc Control Rel Bioact Mater 1990;17:425-426.
33. Montenegro L, Panico AM, Ventimiglia A, Bonina FP: In vitro retinoic acid release and skin permeation from different liposome formulations. Int J Pharm 1996;133:89-96.
34. Sinico C, Manconi M, Peppi M, Lai F, Valenti D, Fadda AM: Liposomes as carriers for dermal delivery of tretinoin: in vitro evaluation of drug permeation and vesicle-skin interaction. J Control Release 2005;103:123-136.
35. Brisaert M, Gabriels M, Matthijs V, Plaizier-Vercammen J: Liposomes with tretinoin: a physical and chemical evaluation. J Pharm Biomed Anal 2001;26:909-917.
36. Ioele G, Cione E, Risoli A, Genchi G, Ragno G: Accelerated photostability study of tretinoin and isotretinoin in liposome formulations. Int J Pharm 2005;293:251-260.
37. Schäfer-Korting M, Korting HC, Ponce-Poschl E: Liposomal tretinoin for uncomplicated acne vulgaris. Clin Investig 1994;72:1086-1091.
38. Patel VB, Misra AN, Marfatia YS: Topical liposomal gel of tretinoin for the treatment of acne: research and clinical implications. Pharm Dev Technol 2000;5:455-464.
39. Patel VB, Misra AN, Marfatia YS: Preparation and comparative clinical evaluation of liposomal gel of benzoyl peroxide for acne. Drug Dev Ind Pharm 2001;27:863-870.
40. Fluhr JW, Barsom O, Gehring W, Gloor M: Antibacterial efficacy of benzoyl peroxide in phospholipid liposomes. A vehicle-controlled, comparative study in patients with papulopustular acne. Dermatology 1999;198:273-277.
41. Patel VB, Misra AN, Marfatia YS: Clinical assessment of the combination therapy with liposomal gels of tretinoin and benzoyl peroxide in acne. AAPS Pharm Sci Tech 2001;2:technical note 4.
42. Burkhart CN, Specht K, Doug Neckers D: Synergistic activity of benzoyl peroxide and erythromycin. Skin Pharmacol Appl Skin Physiol 2000;13:292-296.
43. Nagarsenker MS, Naik B: Design and evaluation of liposomal systems for topical drug delivery (abstract P-117). Proceedings of the International Symposium on Advances in Technology and Business Potential of Novel Drug Delivery Systems 2005;6:133.
44. Hammerstein J, Meckies J, Leo-Rossberg I, Moltz L, Zielske F: Use of cyproterone acetate (CPA) in the treatment of acne, hirsutism and virilism. J Steroid Biochem 1975;6:827-836.
45. Ebling FJ, Thomas AK, Cooke ID, Randall VA, Skinner J: Effect of cyproterone acetate on hair growth, sebaceous secretion and endocrine parameters in a hirsute subject. Br J Dermatol 1977;97:371-381.
46. Miller JA, Wojnarowska FT, Dowd PM, Ashton RE, O'Brien TJ, Griffiths WA, Jacobs HS: Anti-androgen treatment in women with acne: a controlled trial. Br J Dermatol 1986;114:705-716.
47. Pugeat M, Nicolas MH, Dechaud H, Elmidani M: Combination of cyproterone acetate and natural estrogens in the treatment of hirsutism. J Gynecol Obstet Biol Reprod 1991;20:1057-1062.
48. Shaw JC: Antiandrogen therapy in dermatology. Int J Dermatol 1996;35:770-778.
49. Pye RJ, Burton JL, Harris JI: Effect of 1% cyproterone acetate in cetomacrogol cream BPC (formula A) on sebum excretion rate in patients with acne. Br J Dermatol 1976;95:427-428.
50. Gruber DM, Sator MO, Joura EA, Kokoschka EM, Heinze G, Huber JC: Topical cyproterone acetate treatment in women with acne: a placebo-controlled trial. Arch Dermatol 1998;134:459-463.
51. Bhalerao SS, Raje H: Preparation, optimization, characterization, and stability studies of salicylic acid liposomes. Drug Dev Ind Pharm 2003;29:451-467.
52. Biju SS, Ahuja A, Khar RK: Tea tree oil concentration in follicular casts after topical delivery: determination by high-performance thin layer chromatography using a perfused bovine udder model. J Pharm Sci 2005;94:240-245.
53. Touitou E, Dayan N, Bergelson L, Godin B, Eliaz M: Ethosomes - novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. J Control Release 2000;65:403-418.
54. Namdeo A, Jain NK: Niosomes as drug carriers. Ind J Pharm Sci 1996;58:41-46.
55. Uchegbu IF, Vyas SP: Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharm 1998;172:33-70.
56. Hofland HE, Van der Geest R, Bodde HE, Junginger HE, Bouwstra JA: Estradiol permeation from nonionic surfactant vesicles through human stratum corneum in-vitro. Pharm Res 1994;11:659-664.
57. Manconi M, Valenti D, Sinico C, Lai F, Loy G, Fadda AM: Niosomes as carriers for tretinoin. I. Preparation and properties. Int J Pharm 2002;234:237-248.
58. Manconi M, Valenti D, Sinico C, Lai F, Loy G, Fadda AM: Niosomes as carriers for tretinoin. II. Influence of vesicular incorporation on tretinoin photostability. Int J Pharm 2003;260:261-272.
59. Gopinath D, Ravi D, Rao BR, Apte SS, Renuka D, Rambhau D: Ascorbyl palmitate vesicles (Aspasomes): formation, characterization and applications. Int J Pharm 2004;271:95-113.
60. Won R: Method for delivering an active ingredient by controlled time release utilizing a novel delivery vehicle which can be prepared by a process utilizing the active ingredient as porogen. US Patent No 4690825, 1987.
61. Nacht S, Katz M: The Microsponge: A novel topical programmable delivery system; in Osborne D, Amann A (eds): Topical Drug Delivery Formulations. New York, Marcel Dekker, 1990, pp 299-325.
62. Nacht S: Encapsulation and other topical delivery systems. Cosmet Toilet 1995;110:25-30.
63. Embil K, Nacht S: Microsponge delivery systems (MDS) a topical delivery system with reduced irritancy incorporating multiple mechanisms for triggering the release of active agents. J Microencapsul 1996;13:575-588.
64. Froix M, Pukshansky M, Nacht S: Retinoid formulations in porous microspheres for reduced irritation and enhanced stability. US Patent No 5,851,538, 1998.
65. Raritan NJ: Retin A micro product labeling. Ortho Pharmaceutical Corp, 1997.
66. Katz M, Cheng CH, Nacht S: Methods and compositions for topical delivery of benzoyl peroxide. US Patent No 5,879716, 1999.
67. Lawrence MJ, Rees GD: Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev 2000;45:89-121.
68. Kreilgaard M: Influence of microemulsions on cutaneous drug delivery. Adv Drug Deliv Rev 2002;54(suppl 1):S77-S98.
69. Bolzinger MA, Carduner T, Poelman MC: Bi-continuous sucrose ester microemulsion: a new vehicle for topical delivery of niflumic acid. Int J Pharm 1998;176:39-45.
70. Radomska A, Dobrucki R: The use of some ingredients for microemulsion preparation containing retinol and its esters. Int J Pharm 2000;196:131-134.
71. Spiclin P, Gasperlin M, Kmetec V: Stability of ascorbyl palmitate in topical microemulsions. Int J Pharm 2001;222:271-279.
72. El-Laithy HM, El-Shaboury KMF: The development of Cutina lipogels and gel microemulsion for topical administration of fluconazole. AAPS Pharm Sci Tech 2002;3:article 35.
73. Kantaria S, Rees GD, Lawrence MJ: Formulation of electrically conducting microemulsion-based organogels. Int J Pharm 2003;250:65-83.
74. Patravale VB, Mandawgade S, Date AA: Microemulsion based gel of celecoxib: a potential topical delivery system (abstract P-68). Proceedings of the International Symposium on Advances in Technology and Business Potential of Novel Drug Delivery Systems 2004;5:87.
75. Gasco MR, Gallarate M, Pattarino F: In vitro permeation of azelaic acid from microemulsions. Int J Pharm 1991;69:193-196.
76. Ocak F, Kayis A, Celebi N, Erel A: Preparation and evaluation of w/o microemulsion containing metronidazole in acne rosacea (abstract). Proc Control Rel Bioact Mater 2002;29:341.
77. Date AA, Patravale VB: Design of microemulsion based tretinoin gel (abstract A-176). Proceedings of the National Conference on Surfactants and Biocolloids 2003;11:156-157.
78. Trotta M, Ugazio E, Peira E, Pulitano C: Influence of ion pairing on topical delivery of retinoic acid from microemulsions. J Control Release 2003;86:315-321.
79. Date AA, Patravale VB: Microemulsion based erythromycin gel (Abstract AP-89). Proceedings of the Indian Pharmaceutical Congress 2002;54:159.
80. Biju SS, Khar RK, Ahuja A, Chowdhary R: Formulation and evaluation of an effective pH balanced topical antimicrobial product containing tea tree oil. Pharmazie 2005;60:208-211.
81. Hoffman AS: Hydrogels for biomedical applications. Adv Drag Deliv Rev 2002;43:3-12.
82. Lee TW, Kim JC, Sung-Joo Hwanga SJ: Hydrogel patches containing Triclosan for acne treatment. Eur J Pharm Biopharm 2003;56:407-412.
83. Müller RH, Mäder K, Gohla S: Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 2000;50:161-178.
84. Mehnert W, Mader K: Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 2001;47:165-196.
85. Müller RH, Dingler A: The next generation after the liposomes: solid lipid nanoparticles (SLN, Lipopearls) as dermal carrier in cosmetics. Eurocosmetics 1998;7/8:19-26.
86. Schubert MA, Müller-Goymann CC: Solvent injection as a new approach for manufacturing lipid nanoparticles - evaluation of the method and process parameters. Eur J Pharm Biopharm 2003;55:125-131.
87. Jenning V, Gohla S: Encapsulation of retinoids in solid lipid nanoparticles (SLN). J Microencapsul 2001;18:149-158.
88. Wissing SA, Müller RH: A novel sunscreen system based on tocopherol acetate incorporated into solid lipid nanoparticles (SLN). Int J Cosmet Sci 2001;23:233-243.
89. Wissing SA, Müller RH: Cosmetic applications for solid lipid nanoparticles (SLN). Int J Pharm 2003;254:65-68.
90. Wissing SA, Müller RH: Solid lipid nanoparticles as carrier for sunscreens: in vitro release and in vivo skin penetration. J Control Release 2002;81:225-233.
91. Wissing SA, Lippacher A, Müller RH: Investigations on the occlusive properties of solid lipid nanoparticles (SLN™). J Cosmet Sci 2001;52:313-323.
92. Wissing SA, Müller RH: The influence of solid lipid nanoparticles on skin hydration and viscoelasticity - in vivo study. Eur J Pharm Biopharm 2003;56:67-72.
93. Wissing SA, Müller RH: Solid lipid nanoparticles (SLN™) - a novel carrier for UV blockers. Pharmazie 2001;56:783-786.
94. Münster U, Nakamura C, Haberland A, Jores K, Mehnert W, Rummel S, Schaller M, Korting HC, Zouboulis CC, Blume-Peytavi U, Schäfer-Korting M: RU 58841-myristate - prodrug development for topical treatment of acne and androgenetic alopecia. Pharmazie 2005;60:8-12.
95. Patravale VB, Shah K: Solid lipid nanoparticles based tretinoin gels using novel solvent emulsification-diffusion approach (abstract P-39). Proceedings of the International Symposium on Advances in Technology and Business Potential of Novel Drug Delivery Systems 2005;6:55.